A therosclerosis results from chronic inflammation of blood vessels in which vascular endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and macrophages interact to induce pathophysiological changes in the vessel wall. In the early phase of atherosclerosis, vascular ECs express adhesion molecules. Monocytes in circulating blood attach to vascular ECs via those adhesion molecules, infiltrate the vessel wall, and become activated macrophages. These macrophages produce a variety of cytokines, which in turn promote phenotypic modulation/dedifferentiation of VSMCs and induce their migration, hypertrophy, and hyperplasia. 1 Although the accumulated evidence suggests that the reninangiotensin system is implicated in the pathogenesis of atherosclerosis, [2] [3] [4] [5] [6] little is known regarding what kinds of intracellular signaling pathways and transcription factors are implicated in angiotensin II (Ang II)-induced progression of atherosclerosis.
Myocyte enhancer factor 2 (MEF2), related to serum response factor protein, is a family of transcription factors that consists of 4 isoforms: MEF2A, MEF2B, MEF2C, and MEF2D. [7] [8] [9] [10] The MEF2 family of transcription factors appears to cooperate with the MyoD family of transcription factors and to promote the myogenesis of skeletal muscle cells. 11 MEF2C-null mice do not form a normal heart and vascular system, 12, 13 suggesting that MEF2 is required for the development of the cardiovascular system. Although it is not clear whether MEF2 plays critical roles in the pathogenesis of atherosclerosis, we recently reported that MEF2A was a major isoform expressed in VSMCs and that MEF2A expression, its DNA binding activity, and its transactivating function increased when serum-starved VSMCs were restimulated with serum mitogen. 14 These results suggest that MEF2 may play roles in the phenotypic modulation and/or hypertrophy of VSMCs rather than in the maintenance of the differentiated state of VSMCs.
Although the molecular mechanisms of vascular hypertrophy remain unsolved, the mechanisms of cardiac hypertrophy have begun to be unveiled. Recent progress in this field has clearly shown that the Ca 2ϩ -dependent activation of a phosphatase called calcineurin is critically implicated in cardiac hypertrophy. 15 When calcineurin is activated, it dephosphorylates transcription factors called nuclear factors of activated T cells (NFATs), which in turn promote nuclear translocation of NFAT. The NFAT transcription factors then cooperate with nuclear transcription factors such as GATA-4 and stimulate the transcriptional activation of various genes that are involved in cardiac hypertrophy. 16 However, little is known regarding whether the calcineurin/NFAT-dependent pathway is implicated in the phenotypic modulation or hypertrophy of VSMCs.
The difficulty in studying the mechanisms involved in the phenotypic modulation of VSMCs is largely attributable to the lack of any established markers of the dedifferentiated state of VSMCs. Recently, it has been shown that an isoform of myosin heavy chain, known as nonmuscle-type myosin heavy chain B (NMMHCB)/SMemb, is expressed in undifferentiated VSMCs during the embryonic period and that its expression is increased in the neointima of balloon-injured arteries, 17, 18 suggesting that the expression of NMMHCB can be used as a marker of phenotypic modulation of VSMCs. However, it also remains to be determined whether the MEF2-and/or calcineurin/NFAT-dependent pathway is implicated in the expression of NMMHCB.
In the present study, we examined whether Ang II induced the MEF2-and calcineurin/NFAT-dependent transcriptional activation of genes in VSMCs. We also examined whether Ang II induced the expression of NMMHCB and whether the Ang II-induced NMMHCB expression was mediated by the MEF2-or calcineurin/NFAT-dependent pathway. Finally, we examined whether Ang II-induced vascular hypertrophy was mediated by the MEF2-or calcineurin/NFAT-dependent pathway.
Materials and Methods

Reagents
Valsartan (Val) and cyclosporin A (CyA) were kindly supplied by Novartis Pharma AG (Basel, Switzerland), and FK506 (FK) was supplied by Fujisawa Pharmaceutical Co, Ltd (Osaka, Japan). SB203580 (SB) was purchased from Sigma Chemical Co. The anti-MEF2A antibody used for Western blot analyses and anti-NFAT3 antibody were obtained from Santa Cruz Biotechnology. Anti-hemagglutinin antibody was purchased from Roche Molecular Biochemicals.
Cell Culture
Rat VSMCs were cultured from rat thoracic aortas after the explant method, as previously described. 19 Human VSMCs were obtained from Sanko Junyaku and maintained in DMEM containing 20% FBS.
Plasmids
Details of the cloning of human MEF2A wild type, MEF2AS453A (MEF2ASA), in which serine 453 was substituted with alanine, human calcineurin A 1-398 (CalA⌬C), which lacks the carboxylterminal calmodulin binding domain, and MEK6S207A/T211A (MEK6AA, where MEK6 is mitogen-activated protein kinase kinase 6) and MEK6S207E/T211E (MEK6EE), in which serine 207 and threonine 211 were replaced with alanine and glutamic acid, respectively, are described elsewhere (see online supplementary information). Cloning of the human c-jun promoter and human NMMHCB promoter and construction of the heterologous promoter in which 3 copies of the wild-type or mutant NFAT binding site were subcloned upstream from the minimal essential promoter region of the murine c-fos gene are also described elsewhere (see online supplementary information). The carboxyl-terminal coding region of the human c-jun gene was isolated and used for Northern blot analysis as described elsewhere (see online supplementary information).
Transient Transfection
pRL-TK, which encodes the SeaPansy luciferase gene, was purchased from Toyo Ink and used as the internal control for the luciferase assays. With the use of lipofectAMINE (Life Technologies), rat VSMCs were transiently transfected with reporter plasmids encoding the wild-type or mutant c-jun promoter, putative NFAT binding sites upstream from the murine c-fos minimal essential promoter, or NMMHCB promoter, along with pRL-TK. Rat VSMCs were then stimulated with 10 Ϫ7 mol/L Ang II for 48 to 96 hours and harvested for luciferase assays. In some experiments, cells were pretreated with 100 nmol/L Val, 1 mol/L CyA, 1 mol/L FK, or 10 mol/L SB and stimulated with 10 Ϫ7 mol/L Ang II. Rat VSMCs were also cotransfected with MEF2ASA, MEK6AA, MEK6EE, or CalA⌬C in some experiments to examine the effects of these mutants on the activities of those promoters. Dual luciferase assay was performed by using a luminometer (Lumat LB 9507, Berthold).
Construction of a Replication-Defective Adenovirus
A replication-defective adenovirus that expresses hemagglutinin-tagged MEF2ASA (AdMEF2ASA) or CalA⌬C (AdCalA⌬C) was constructed with the use of an AdMax kit (Microbix Biosystems Inc) by the methods recommended by the manufacturer. The protein-coding region of MEF2ASA and CalA⌬C was ligated to the pDC516 vector and cotransfected into 293 cells along with pBHGfrt⌬E1,3FLP. Recombinant adenoviruses were generated through homologous recombination, propagated in 293 cells, and, finally, purified by CsCl gradient ultracentrifugation. A recombinant adenovirus that expresses green fluorescence protein (AdGFP) was obtained from Quantum Biotechnologies.
Western Blot Analysis
Protein extraction for Western blot analyses was performed as previously described. 20 Antibodies were used at a dilution of 1:200 except for anti-NMMHCB antibody, which was used at a dilution of 1:1000. The details of the preparation of anti-NMMHCB antibody used in the present study have previously been described. 21 
Electrophoretic Mobility Shift Assays
VSMCs were serum-starved for 3 days and stimulated with 10 Ϫ7 mol/L Ang II for 8 hours. Whole-cell extracts were prepared from rat VSMCs as described previously. 14 Probes and competitor DNAs were double-stranded synthetic oligonucleotides that were prepared according to the sequence of the MEF2 binding site from the human c-jun promoter and the NFAT binding site from the human interleukin-2 promoter. The nucleotide sequences of the sense strand of the double-stranded oligonucleotides were as follows: for wildtype MEF2, 5Ј-TGGGCTATTTTTAGGGGTTGACTG-3Ј; for mutant MEF2, 5Ј-TGGGCTATTgccAGGGGTTGACTG-3Ј; for wildtype NFAT, 5Ј-CTACATTGGAAAATTTTATTACACGAGCT-3Ј; and for mutant NFAT, 5Ј-CTACATTGGcccATTTTATT-ACACGAGCT-3Ј.
The lowercase bold letters depict nucleotide substitutions to induce point mutations. Electrophoretic mobility shift assays (EMSAs) were performed as previously described. 14 A highly specific anti-MEF2A antibody used for supershift assay has previously been described. 14 
Northern Blot Analysis
Total RNA was extracted by using TRIZOL Reagent (GIBCO-BRL) according to the instructions provided by the manufacturer. Northern blot analysis was performed as previously described. 22 
Measurement of [ 3 H]Leucine Incorporation
VSMCs were serum-starved for 3 days and radiolabeled with [ 3 H]leucine (2 Ci/mL, Amersham) for 2 hours. Cells were washed twice with ice-cold PBS and incubated with ice-cold 10% trichloroacetic acid for 30 minutes. After being washed with distilled water, the cells were lysed with 0.2N NaOH, neutralized with 0.2N HCl, and subjected to liquid scintillation counting.
Statistical Analysis
The values are meanϮSEM. Statistical analyses were performed by ANOVA, followed by the Student-Newman-Keuls test. Differences with a value of PϽ0.05 were considered statistically significant. An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
Results
Ang II Induces DNA Binding Activity of MEF2A in VSMCs
We first examined whether Ang II induced the DNA binding activity of MEF2A. Ang II significantly increased the DNA binding activity of MEF2 in rat VSMCs (2.1Ϯ0.12-fold compared with control level, PϽ0.001; nϭ3) ( Figure 1 ). The authenticity of the DNA-protein complexes was confirmed by cold competition experiments in which a 100ϫ molar excess of double-stranded oligonucleotides encoding a wild-type or mutant MEF2 binding site was included in the reaction mixture and by use of a highly specific anti-MEF2A antibody, 14 which supershifted the DNA-protein complexes. The Ang II-induced increase of MEF2A DNA binding activity was significantly suppressed when rat VSMCs were preincubated with 100 nmol/L Val (1.2Ϯ0.03-fold increase compared with control level, PϽ0.01 versus Ang II stimulation; nϭ3). In marked contrast, pretreatment with the p38 inhibitor SB or the calcineurin inhibitors FK and CyA did not remarkably inhibit the Ang II-induced increase of MEF2A DNA binding activity. We also confirmed that Ang II significantly increased the expression of MEF2A protein without affecting the expression levels of MEF2A transcripts (see online Figure 1 ).
Ang II-Induced Transcriptional Activation of c-jun Gene Is Mediated by MEF2-and p38-Dependent Pathways
To examine the roles of MEF2 in gene transcription in VSMCs, we used the human c-jun promoter because it has been reported that MEF2 is critically implicated in the transcriptional activation of the c-jun gene. 23, 24 Luciferase reporter constructs containing the wild-type human c-jun promoter (c-junwt promoter) or a mutant c-jun promoter (c-junmut promoter), in which the consensus MEF2 binding site was mutated, were transfected in VSMCs, and the cells were stimulated with Ang II. Ang II significantly increased the activity of the c-junwt promoter ( Figure 2A ). This increase was significantly suppressed by pretreatment with Val, whereas CyA or FK did not significantly inhibit the Ang II-induced increase of the c-junwt promoter activity. It has been suggested in several reports that MEF2CS387A, in which serine 387 of human MEF2C is replaced with alanine, works as a dominant-negative mutant of MEF2C. 23, 25 We found that serine 453 of human MEF2A is located in a similar alignment of amino acid sequences with serine 387 of human MEF2C. We substituted serine 453 with alanine (MEF2ASA) and examined whether it worked as a dominant-negative mutant. The Ang II-stimulated activation of the c-junwt promoter was significantly inhibited to the nonstimulated control level by cotransfection with MEF2ASA, suggesting that this mutant worked as a dominant-negative mutant and that Ang II-induced c-junwt promoter activation was mediated by the MEF2-dependent pathway. Because it has been reported that the p38-dependent phosphorylation and activation of MEF2 are implicated in the transcriptional activation of genes, especially the c-jun gene, 23, 24 we used dominantnegative and constitutively active mutants of MEK6, a kinase that activates p38. When MEK6AA was cotransfected with the reporter plasmid encoding the c-junwt promoter, Ang II-induced activation of the c-junwt promoter was suppressed to the control level, suggesting that the MEK6/p38-dependent pathway was involved in the Ang II-induced activation of the c-jun gene. In accordance with the result, SB significantly inhibited the Ang II-induced increase of the c-junwt promoter activity. Furthermore, MEK6EE significantly increased the activity of the c-junwt promoter in the absence of Ang II. In contrast, the constitutively active mutant of human calcineurin A, CalA⌬C, did not promote the activation of the c-junwt promoter. We also used the c-junmut promoter. Ang II did not remarkably stimulate the activity of the c-junmut promoter. This result also supported our findings that Ang II stimulated the activity of the c-jun promoter via the MEF2-dependent pathway. Although MEK6EE stimulated the activity of the c-junmut promoter, the extent was smaller than that observed when the c-junwt promoter was used. CalA⌬C did not stimulate the activity of the c-junmut promoter. Interestingly, forced expression of wild-type MEF2A decreased the activity of the c-junwt promoter, probably because MEF2A homodimers inhibited the formation of MEF2A heterodimers. A similar phenomenon was observed when MEF2C was EMSAs were performed by using a radiolabeled doublestranded oligonucleotide probe encoding a putative MEF2 binding site located in the promoter region of the human c-jun gene. Competition experiments were performed by using a 100ϫ molar excess of cold double-stranded oligonucleotides encoding the wild-type or a mutant MEF2 binding site. Anti-MEF2A antibody was also used to show the specificity of the protein-DNA complexes. The arrow indicates the position of the DNAprotein complexes.
overexpressed along with a reporter plasmid encoding the wild-type c-jun promoter. 23 Expression of the mutants used in these experiments was confirmed by Western blot analyses (see online Figure 2A ). To confirm the involvement of MEF2A in the activation of the endogenous c-jun gene, we infected VSMCs with AdMEF2ASA and stimulated the cells with Ang II. Northern blot analysis showed that the Ang II-induced increase of c-jun gene expression was suppressed to the nonstimulated control level by infection with AdMEF2ASA ( Figure 2B ). The expression of AdMEF2ASA in VSMCs was confirmed by Western blot analysis (see online Figure 2B ).
Ang II Induces DNA Binding Activity of NFAT in VSMCs
We next examined whether Ang II stimulated the DNA binding activity of NFAT in VSMCs. Ang II significantly increased the formation of DNA-protein complexes (2.2Ϯ0.3-fold compared with control level, PϽ0.05; nϭ3) ( Figure 3A ). These DNA-protein complexes were abolished when the reaction mixture contained a 100ϫ molar excess of the double-stranded oligonucleotide encoding the wild-type NFAT binding site but not when it contained a 100ϫ molar excess of the oligonucleotide encoding the mutant NFAT binding site, suggesting the specificity of the bands. The intensity of the bands corresponding to the DNA-protein complexes was significantly reduced when rat VSMCs were pretreated with Val (1.1Ϯ0.1-fold increase compared with control level, PϽ0.05 versus Ang II stimulation; nϭ3), CyA (1.1Ϯ0.2-fold increase compared with control level, PϽ0.05 mol/L Ang II for 48 hours, and cells were harvested for the luciferase assay. The total amounts of plasmid DNA transfected in VSMCs were adjusted by using the expression vector pcDNA3. SeaPansy luciferase activity was used as the internal control. The relative luciferase activity observed in control cells transfected with the wild-type c-jun promoter construct was calculated as 1.0, and the fold induction in each group is indicated. *PϽ0.001 vs control; #PϽ0.01 vs Ang II stimulation (nϭ6). B, VSMCs were infected with the indicated multiplicity of infection (MOI) of AdGFP or AdMEF2ASA when the culture medium was changed to low-serum medium. After 3 days, VSMCs were stimulated with 10 Ϫ7 mol/L Ang II for 30 minutes, and 30 g of total RNA was electrophoresed for Northern blot analysis. The membranes were hybridized with a 32 P-labeled cDNA probe prepared from human c-jun cDNA. The membranes were then reprobed with a cDNA probe encoding GAPDH. Shown is a representative result of 2 independent experiments in which the same result was obtained. versus Ang II stimulation; nϭ3), or FK (1.1Ϯ0.1-fold increase compared with control level, PϽ0.05 versus Ang II stimulation; nϭ3), indicating that the Ang II-induced formation of the DNA-protein complexes was mediated by its type 1 receptor-dependent and calcineurin-dependent pathways. To examine more specifically whether the NFAT family of transcription factors was included in the complexes, we used an anti-NFAT3 antibody because it has been reported that NFAT3 is expressed in cardiac muscles, which, developmentally, have properties similar to those of VSMCs. 15 We used human VSMCs in this case because the antibody used in the present study was designed to react specifically with human NFAT3. A single band corresponding to a DNA-protein complex was detected, and the density of the band was remarkably increased when human VSMCs were stimulated with Ang II (Figure 3B ). The DNA-protein complex was competed away by a 100ϫ molar excess of the wild-type double-stranded oligonucleotide but not by the mutant double-stranded oligonucleotide. Importantly, the intensity of the band corresponding to the DNA-protein complex was diminished when the reaction mixture contained the anti-NFAT3 antibody but not when it contained nonimmune serum. These results suggested that Ang II stimulated the DNA binding activity of the NFAT family of transcription factors and that at least NFAT3 was expressed in VSMCs.
Ang II Promotes Calcineurin/NFAT-Dependent Gene Activation in VSMCs
To examine whether Ang II induced the transcriptional activation of genes via the calcineurin/NFAT-dependent pathway in VSMCs, we prepared heterologous promoter constructs in which 3 copies of the wild-type (pGL2-3XNFATwt) or mutant (pGL2-3XNFATmut) NFAT binding site were subcloned upstream from the minimal essential promoter region of the murine c-fos gene ( Figure 4A ). Ang II significantly increased the promoter activity of pGL2-3XNFATwt ( Figure 4B ). This increase was significantly suppressed when VSMCs were pretreated with Val, CyA, or FK. Furthermore, CalA⌬C significantly increased the activity of pGL2-3XNFATwt in the absence of Ang II. In marked contrast, Ang II did not significantly increase the activity of pGL2-3XNFATmut, nor did CalA⌬C significantly increase the promoter activity of pGL2-3XNFATmut. These results suggested that Ang II promoted the NFAT-dependent transcriptional activation of genes via its type 1 receptordependent and calcineurin-dependent pathways in VSMCs.
Ang II Induces Transcriptional Activation of the NMMHCB Gene via the Calcineurin/NFATDependent Pathway but Not via the MEF2-Dependent Pathway in VSMCs
We next examined whether Ang II stimulated the NMMHCB promoter activity and whether Ang II-induced activation of the NMMHCB gene was mediated by the MEF2-and/or calcineurin/NFAT-dependent pathways in VSMCs. Although the isolated human NMMHCB promoter region did not contain any consensus MEF2 or NFAT binding sites, Ang II significantly increased the activity of the NMMHCB promoter, and this increase was significantly suppressed to the control level by pretreatment with Val ( Figure 5A ). Ang II-induced activation of the NMMHCB promoter was partially but significantly inhibited by pretreatment with CyA and FK. In accordance with the results, CalA⌬C significantly increased the activity of the NMMHCB promoter in the absence of Ang II. In contrast, the Ang II-induced increase of NMMHCB promoter activity was not significantly inhibited by pretreatment with SB or by cotransfection with MEF2ASA or MEK6AA. The results were further supported by the finding that overexpression of wild-type MEF2A or MEK6EE did not significantly increase the activity of the NMMHCB promoter. To further confirm the results, we infected VSMCs with AdMEF2ASA or AdCalA⌬C and examined their effects. Ang II-induced expression of NMMHCB was remarkably suppressed by pretreatment with Val, CyA, or FK but not by infection with AdMEF2ASA ( Figure 5B ). Furthermore, AdCalA⌬C infection increased NMMHCB expression in the absence of Ang II, and this increase was inhibited by CyA. The expression of AdCalA⌬C mol/L Ang II for 48 hours, and cells were harvested for the luciferase assay. The total amounts of plasmid DNA transfected in VSMCs were adjusted by using the expression vector pcDNA3. SeaPansy luciferase activity was used as the internal control. The relative luciferase activity observed in control cells transfected with the reporter construct encoding 3 copies of the wild-type NFAT binding site was calculated as 1.0, and the fold induction in each group is indicated. *PϽ0.001 vs control; #PϽ0.001 vs Ang II stimulation (nϭ6).
in VSMCs was confirmed by Western blot analysis (online Figure 2B ). These results suggested that the Ang II-induced activation of the NMMHCB gene was, at least in part, mediated by the calcineurin/NFAT-dependent pathway but not by the MEF2-or p38-dependent pathway in VSMCs.
Ang II Promotes Protein Synthesis via the MEF2-Dependent Pathway but Not the Calcineurin/NFAT-Dependent Pathway in VSMCs
We finally examined whether the MEF2-and/or calcineurin/ NFAT-dependent pathway was implicated in vascular hypertrophy ( Figure 6) 
Discussion
Although we have reported that MEF2A is a major isoform expressed in VSMCs and that its expression is upregulated when serum-starved VSMCs are restimulated with serum mitogens, 14 the functions of MEF2 in VSMCs remain to be elucidated. Therefore, we examined whether MEF2 was implicated in Ang II-induced phenotypic modulation and/or hypertrophy of vascular myocytes. Ang II stimulated the DNA binding activity of MEF2A and its expression at the protein level without affecting the expression level of MEF2A transcripts (see online Figure 1 ), suggesting a posttranscriptional regulation of MEF2A expression by Ang II in VSMCs. It has been found that although MEF2 transcripts are widely expressed in various tissues, the expression of the MEF2 protein and its transactivating function are found in more restricted tissues, 7, 8, 26 suggesting a translational regulation of MEF2 expression. In fact, a translational repression Ϫ7 mol/L Ang II for 72 hours, and cells were harvested for the luciferase assay. The total amounts of plasmid DNA transfected in VSMCs were adjusted by using the expression vector pcDNA3. SeaPansy luciferase activity was used as the internal control. The relative luciferase activity observed in control cells was calculated as 1.0, and the fold induction in each group is indicated. *PϽ0.01 vs control; #PϽ0.01 vs Ang II stimulation; and ##PϽ0.05 vs Ang II stimulation (nϭ6). B, VSMCs were infected with the indicated MOI of AdMEF2ASA, AdGFP, or AdCalA⌬C when the culture medium was changed to low-serum medium. After 3 days, VSMCs were stimulated with 10 Ϫ7 mol/L Ang II for 3 days. In some experiments, VSMCs were pretreated with 100 nmol/L Val, 1 mol/L FK, or 1 mol/L CyA. Fifty micrograms of each protein extract was used for Western blot analysis. Shown is a representative result of 2 independent experiments in which the same result was obtained. element was identified in the 3Ј untranslated region of mouse MEF2A transcripts. 27 Thus, our results are compatible with the previous finding that MEF2 expression is regulated at the translational level.
Ang II induced a transcriptional activation of the c-jun gene, and this increase was inhibited by MEF2ASA, MEK6AA, and SB but not by CyA or FK. The activity of the c-jun promoter was increased by cotransfection with MEK6EE in the absence of Ang II but not by cotransfection with CalA⌬C. Furthermore, when a mutant of the c-jun promoter in which the consensus MEF2 binding site was mutated was used, the Ang II-induced increase of the mutant c-jun promoter activity was minimal, and MEK6EE-stimulated activation was smaller than that observed for the wild-type c-jun promoter. These results are compatible with previous findings that the activation of the c-jun gene is, at least in part, mediated by the MEF2 family of transcription factors and that p38-induced phosphorylation of MEF2 is involved in the transactivating function of MEF2. 23, 24 Although the Ang II-induced increase of MEF2A DNA binding activity was not affected by the p38 inhibitor SB, the Ang II-induced increase of c-jun promoter activity was significantly inhibited by SB and MEK6AA. A similar dissociation of the DNA binding activity and transactivating function of MEF2 has previously been reported. The calcineurinmediated pathway stimulated the transactivating function of MEF2A without affecting its DNA binding activity in skeletal muscle cells. 28 Thus, it appears that not only DNA binding of MEF2 but also posttranslational modifications such as phosphorylation or changes in its association with other nuclear factors are required for the MEF2-dependent transcriptional activation of genes.
Although it is well known that the calcineurin/NFATdependent pathway is implicated in the development of cardiac hypertrophy, the role of this pathway in VSMCs has not been clarified. We found that Ang II stimulated the DNA binding activity of NFAT and the NFAT-dependent transcriptional activation of genes, which were inhibited by CyA and FK. We also found that among the NFAT family of transcription factors, at least NFAT3 was expressed in VSMCs. It has been reported that NFAT1 (NFATp) and NFAT2 (NFATc) were expressed in VSMCs by using Western blot analysis and immunostaining, although the expression of NFAT3 was not examined in that study. 29 Thus, several isoforms of the NFAT transcription factors may be expressed in VSMCs.
Although the promoter region of human NMMHCB does not contain any canonical MEF2 or NFAT binding site, Ang II stimulated the NMMHCB promoter activity, and this increase was partly mediated by the calcineurin/NFATdependent pathway but not by the MEF2-or p38-dependent pathway in VSMCs. Little is known about genes expressed in VSMCs whose promoter regions contain NFAT binding sites. However, the NFAT transcription factors, reportedly, do not always need to directly bind to DNA to induce a transcriptional activation of genes. NFATp enhanced the transcriptional activity of MEF2D by recruiting p300 without binding to DNA in T cells. 30 Furthermore, it is known that genes activated during cardiac hypertrophy do not always possess NFAT binding sites in their promoters. 16 Therefore, further studies are required to elucidate what kinds of genes are activated via the calcineurin/NFAT-dependent pathway during phenotypic modulation of VSMCs.
Surprisingly, Ang II-induced protein synthesis (hypertrophy) was mediated by the MEF2-dependent pathway but not by the calcineurin/NFAT-dependent pathway in VSMCs. It is of note that Ang II reportedly stimulates the production of reactive oxygen species (ROS) in VSMCs 4 and that ROS and p38 are implicated in Ang II-induced protein synthesis. 31 Therefore, it is possible that Ang II induces vascular hypertrophy via the ROS/p38/MEF2-dependent pathway. Collectively, our results indicate that MEF2 and calcineurin/NFAT have, at least partly, distinct roles in VSMCs. MEF2 appears to be implicated in vascular hypertrophy, whereas calcineurin/NFAT appears to be involved in phenotypic modulation, although both of them may be involved in the activation of the same genes in some cases.
In summary, Ang II induced the MEF2A-and calcineurin/ NFAT-dependent transcriptional activation of genes in VSMCs. These pathways may be implicated in the pathological changes of VSMCs, such as dedifferentiation, hypertrophy, and hyperplasia, observed in atherosclerotic lesions. Modulation of these pathways may be a useful strategy in inhibiting the progression of atherosclerosis. 
MATERIALS AND METHODS
The amino terminally HA-tagged human MEF2A cDNA was prepared by polymerase chain reaction (PCR) using a human MEF2A cDNA clone previously isolated. VSMCs. One µg of total RNA was subjected to reverse transcription using a random primer, and PCR was performed. The PCR primers used were as follows: cjunsenseprimer; 5'-GCCGGTCTACGCAAACCTCAG-3', c-junantisenseprimer; 5'-GCACCCACTGTTAACGTGGTTC-3'. The PCR-amplified product was digested with BamH I
and EcoR I, and subcloned in pBluescript SK(+) vector (Stratagene, La Jolla, CA).
The insert was excised and used as a cDNA probe for Northern blot analysis. The full-length human MEF2A cDNA was also excised from the pcDNA3HA vector and used as a cDNA probe for Northern blot analysis. The nucleotide sequences of the all constructs were confirmed by cycle sequencing using an ABI PRISM 310 Genetic
Analyzer (Perkin-Elmer, Foster, CA).
RESULTS
We examined whether ATII increased MEF2A protein expression in VSMCs.
MEF2A was detected as two separate bands as we previously reported, 1 probably reflecting differences in posttranslational status such as phosphorylation. When rat VSMCs were stimulated with 10 -7 M ATII, expression of the MEF2A protein increased in a time-dependent manner (8 hrs poststimulation; 1.5±0.02 fold increase compared with control level, n=3, P<0.01) (online Figure 1A) . ATII-induced increase of MEF2A expression was substantially inhibited when rat VSMCs were pretreated with 100 nM Val which was reported to be a highly specific antagonist for ATII type 1 receptors 3 (Online Figure 1B) , suggesting that ATII promoted MEF2A expression via its type 1 receptor. We also examined the expression of MEF2A transcripts. The results of Northern blot analysis showed a complex expression pattern of MEF2A transcripts. At least, three bands were detected. A similar expression pattern of the MEF2A transcripts was previously reported. 4 The expression of MEF2A transcripts was not remarkably affected by ATII stimulation (Online Figure 1C) . The result was compatible with our previous report that MEF2A expression was regulated at the translational level in VSMCs. and CalA∆C. The expression plasmids used in this study were transfected in COS7 cells, and 100 µg of each protein extract was used for Western blot analysis to confirm the expression of these mutants. Protein extracts prepared from nontransfected COS7 cells were used as the control (C). Anti-HA antibody was used to detect the expression of these mutants except for the MEF2A constructs in which anti-MEF2A antibody was used. B) Expression of AdMEF2ASA and AdCalA∆C in
VSMCs. Twenty MOI of AdMEF2ASA or AdCalA∆C was used to infect rat VSMCs and 100 µg of each protein extract was used for Western blot analysis to confirm the expression of these viruses. Protein extracts prepared from non-infected rat VSMCs were used as the control (C). Anti-HA antibody was used to detect the expression of CalA∆C while anti-MEF2A antibody was used to detect MEF2ASA.
